Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma

Key Points

• This research aims to explore how regorafenib affects PD-L1 and IDO1 expression to boost antitumor immunity in melanoma.
• Utilized a combination of immunotherapy and regorafenib
• Focused on melanoma cases with RET/Src axis activation
• Examined IFNγ-induced expression levels of PD-L1 and IDO1
• Regorafenib significantly reduced PD-L1 expression in response to IFNγ
• Inhibition of IDO1 was also observed, contributing to enhanced immunity
• Foundational rationale provided for clinical exploration of this treatment combination